Prestige Consumer Healthcare Inc. (PBH) stock intrinsic value fair value estimate & owner earnings analysis

Prestige Consumer Healthcare owns a portfolio of over-the-counter health brands. It markets them and mostly outsources their manufacture. The brands include Monistat, Summer's Eve, Dramamine, Fleet, BC and Goody's, Clear Eyes, Debrox, Compound W, Chloraseptic, Luden's, DenTek and TheraTears, plus Hydralyte internationally. Since June 2026 the portfolio also includes Breathe Right nasal strips, Dimetapp and Anbesol, and since July 2026 LaCorium Health's Dermal Therapy skin-care line in Australia. Most brands hold leading positions in narrow niches where shoppers buy by name. About 85% of sales are in North America. Walmart (about 20% of gross sales) and Amazon (about 15%) are the largest customers. Earning power. We measure owner earnings as the cash the business generates after stock-based pay and the capital spending needed to keep it running, and after setting aside year-to-year swings in working capital. On that basis the company earned between $4.86 and $5.32 per share in each of the last five fiscal years (years end in March). The median is about $257 million a year. Beneath that, the existing business has not grown: revenue was $1,087 million in fiscal 2022 and $1,089 million in fiscal 2026, and owner earnings were $247 million and $245 million. Per-share gains came from buybacks, and some of the dollar gains in 2023-2025 came from lower interest as debt was paid down, not from the brands. Fiscal 2026 owner earnings fell 7.9%. Nearly all of the revenue decline came from Eye & Ear Care, which fell from about $183 million to $143 million because Clear Eyes suppliers could not meet demand. Clear Eyes is now under 3% of sales. What changed. We have revised this analysis twice. First, we corrected the profit of the acquired Breathe Right portfolio. We had estimated $50-60 million a year before interest. The historical statements the company filed with the acquisition show about $196 million of sales and $58 million of operating profit, after $29 million of non-cash amortization on the seller's books. Before that charge the brands earned about $88 million, a 45% margin. That correction raised our estimate. Second, we removed growth that the record does not support. Our earlier cases grew the existing brands 1.5% a year in the base case and 2.5% in the bull case. Given four years of flat revenue and earnings, the base case now assumes no growth. We also removed an assumed recovery at the Pillar5 plant from the base case, because the company has given no timeline for it. Taken together, our base value moves from about $92 per share in our original analysis to about $72.50. Recent developments. Pillar5, the Ontario eye-drop plant bought in December 2025 to fix the Clear Eyes supply problem, is still being repaired. In the June 2026 quarter it cost $7.1 million in remediation and idle-plant costs, and supply is still constrained. Sales in that quarter rose 6.5% to $265.7 million, and 3.2% excluding acquisitions and currency. Gross margin fell from 56.2% to 51.3%, because of the Pillar5 costs and a $2.8 million one-time charge on acquired inventory. The quarter also carried $12.8 million of deal costs, which we treat as one-time. Only about two weeks of Breathe Right appear in the quarter, so the combined business has not yet reported a clean period. In July 2026 the company replaced its 5.125% notes due 2028 with $400 million of 6.25% notes due 2034. That leaves no maturities before 2031, at higher interest. Debt. The $1.045 billion purchase was paid for with a new seven-year term loan at a floating rate of SOFR plus 2.00%. The company's own pro forma assumed 5.63%, about $62 million of interest a year. A further $95 million was borrowed for LaCorium. Debt is now about $2.1 billion, roughly four times annual earnings before interest, taxes, depreciation and amortization. This reverses most of the debt reduction achieved between 2017 and 2025. The deal was an asset purchase, so about $1 billion of the price can be deducted for tax over 15 years. That saves roughly $17 million a year in cash taxes until about 2041. Accounting judgements. Owner earnings start from operating cash flow, which adds back book amortization of acquired brands (about $18 million a year) and past brand write-downs. The company has written down brands repeatedly: $100 million in fiscal 2018, $229 million in 2019 and $370 million in 2023. The 2023 charge covered Summer's Eve, DenTek and TheraTears, less than two years after TheraTears was bought. We do not cut the earnings level for this. Instead, that record is why every case except the bull case has the brands slowly shrinking in the long run. Cash earnings are measured after interest, so we do not also subtract debt from the value. Leverage enters the cases through interest rates and refinancing. The company has paid $15-23 million a year less cash tax than its reported tax expense, largely from tax deductions on brands bought in earlier deals. Those deductions run 15 years, and in our judgement some of the older ones expire soon, so every case assumes cash taxes rise. We use the acquired brands' margin from the seller's statements only in the bull case. The base case uses 40%, because the seller's split of overhead costs may understate what these brands really cost to run. All cases are discounted at 6%. Base case, about $72.50 per share. The existing brands earn about $234 million in the first year. That is below fiscal 2026 because Pillar5's plant costs run for a full year and are assumed to continue. It is still a smaller decline than fiscal 2026's 7.9% fall, for two reasons: most of the Clear Eyes loss has already been absorbed, and sales excluding acquisitions grew 3.2% in the latest quarter. The existing brands then stay flat for ten years, matching their record, and shrink 1% a year after that. Breathe Right, Dimetapp and Anbesol earn about $78 million before interest (40% of $196 million), stay flat for ten years, then shrink 1% a year. The term loan costs 5.75%. After tax and the tax deduction, the acquired brands add about $31 million a year. That falls by about $17 million once the deduction runs out in year fifteen. The 2031 notes are refinanced at 6.25%. Cash taxes rise by $8 million from year two and $14 million from year six. Working capital absorbs $5 million a year for a decade. Owner earnings are about $5.40 per share in year one and about $4.87 in year ten. About $37 of the value comes from the first ten years. Bear case, about $46 per share. The existing brands start near $229 million and shrink 1% a year from the start, then 3% a year after year ten, as more brands follow Summer's Eve and DenTek downward. Pillar5 never recovers and Clear Eyes does not come back. The acquired portfolio has $180 million of sales at a 35% margin and shrinks at the same pace. The term loan costs 6.5%, the 2031 notes are refinanced at 7%, cash taxes rise sooner and by more, and working capital absorbs $12 million a year for a decade. In this case the acquired brands earn less than their interest once the tax deduction ends. High debt and dependence on Walmart and Amazon are what make this downside realistic. Bull case, about $110 per share. Pillar5 is fixed within two years and Clear Eyes supply is restored, adding about $29 million a year after tax. This is the reason the plant was bought. The existing brands grow 1.5% a year for ten years through continued price increases, then hold flat. The acquired brands keep the 45% margin shown on the seller's books and grow 1% a year for ten years. Faster debt paydown holds the term-loan cost near 5.25%. What would make this wrong: the acquired brands' profits proving lower under Prestige than on the seller's books, a lasting loss of shelf space at Walmart or Amazon, Pillar5 never producing reliably, or a sharp rise in short-term rates on more than $1.1 billion of floating-rate debt. The combined business has reported only two weeks with Breathe Right, so the acquisition figures rest on the seller's historical statements rather than Prestige's own results. Because the company is heavily indebted, its brands have not grown, and it has a record of overpaying for brands, the margin-of-safety price sits well below the base value.